The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi.
D000818:Animals; D001667:Binding, Competitive / Q000276:immunology; D037282:Calreticulin / Q000378:metabolism / Q000502:physiology*; D003094:Collagen / Q000378:metabolism; D015922:Complement C1q / Q000037:antagonists & inhibitors / Q000378:metabolism; D003169:Complement Inactivator Proteins / Q000378:metabolism / Q000502:physiology*; D003171:Complement Pathway, Classical / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000378:metabolism; D008358:Mannose / Q000378:metabolism; D037601:Mannose-Binding Lectin / Q000037:antagonists & inhibitors / Q000378:metabolism; D008565:Membrane Proteins / Q000378:metabolism / Q000502:physiology; D018613:Microscopy, Confocal; D010446:Peptide Fragments / Q000378:metabolism / Q000502:physiology; D011485:Protein Binding / Q000276:immunology; D017434:Protein Structure, Tertiary; D014349:Trypanosoma cruzi / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity
D037282:Calreticulin; D003169:Complement Inactivator Proteins; D007166:Immunosuppressive Agents; D037601:Mannose-Binding Lectin; D008565:Membrane Proteins; D010446:Peptide Fragments; D015922:Complement C1q; D003094:Collagen; D008358:Mannose